New drug combo targets Hard-to-Treat cancers

NCT ID NCT06544655

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 20 times

Summary

This early-phase study tests a new drug, BMS-986484, alone or with another drug (nivolumab) in people with advanced solid tumors like lung, colorectal, pancreatic, stomach, and head/neck cancers. The main goal is to check safety and find the right dose. About 213 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Local Institution - 0003

    Tucson, Arizona, 85719, United States

  • Local Institution - 0004

    Sioux Falls, South Dakota, 57104, United States

  • Local Institution - 0007

    Los Angeles, California, 90033, United States

  • Local Institution - 0011

    Grand Rapids, Michigan, 49546, United States

  • Local Institution - 0013

    San Antonio, Texas, 78229, United States

  • Local Institution - 0016

    Montreal, Quebec, H2X 0A9, Canada

  • Local Institution - 0017

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 0019

    Elizabeth Vale, South Australia, 5112, Australia

  • Local Institution - 0021

    Darlinghurst, New South Wales, 2010, Australia

Conditions

Explore the condition pages connected to this study.